Infectious Disease Diagnostics Market by Product (Reagents, Kits, Instrument, Software), Test Type (Lab, POC), Disease (COVID-19, Flu, HAIs, HIV, HPV), Technology (Immunodiagnostics, NGS, INAAT, PCR), End User (Hospitals, Labs)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

The global Infectious Disease Diagnostics market size was exhibited at USD 35. 9 billion in 2022 and is projected to hit around USD 31.2 billion by 2032, growing at a CAGR of -1.5% during the forecast period 2023 to 2032.

Market growth is driven by the global prevalence of infectious diseases and the growing awareness for early disease diagnosis, shift in focus from centralized laboratories to decentralized POC testing and rising technological advancements.

COVID-19 is an infectious disease caused by the novel coronavirus. Largely unknown before the outbreak began in Wuhan (China) in December 2019, COVID-19 moved from a regional crisis to a global pandemic in just a few weeks. The World Health Organization (WHO) declared COVID-19 a pandemic on March 11, 2020.

Since testing remains a crucial step in controlling the rapid spread of the disease, government organizations worldwide are supporting laboratories in streamlining COVID-19 testing procedures.The COVID-19 pandemic negatively affected the overall sales of most of the companies but had an positive impact on the infectious disease diagnostics market because of the use of infectious disease diagnostic methods for COVID-19 testing.

In line with this, regulatory authorities utilized methods to speed up the approval of COVID-19 diagnostic products. Moreover, major companies have undertaken strategic developments to introduce COVID-19 rapid tests and nullify the impact of COVID-19 on their operational capabilities, as diagnostic testing remains the backbone of the COVID-19 response, supporting containment efforts to mitigate the outbreak. Also, the severity of this crisis and increasing capacity issues associated with PCR-based testing accelerated the development of diagnostic solutions to meet the demands for mass testing. Major companies operating in this market scaled up their operations for testing and tracking COVID-19.

However, the COVID-19 pandemic has continued to show a strong decline in the world this year, with contaminations decelerating everywhere, leading to a decrease in the growth rate of the infectious disease diagnostics market. Since the start of the COVID-19 outbreak, the WHO has worked with countries and areas in the Western Pacific Region on public health measures to slow or stop the spread of the virus. Vaccines are an important tool, in combination with other measures, to protect people against COVID-19 and reduce widescale social disruption.

Infectious Disease Diagnostics Market Report Scope

 Market Dynamics

Driver: Global prevalence of infectious diseases

The prevalence of infectious diseases in developed and developing regions will positively influence the growth of the infectious disease diagnostics market. The diagnosis and management of such diseases are responsible for the increasing number of prescriptions for infectious disease diagnostic tests. These factors, alongside the growing trend for preventive medicine, is expected to drive the demand for infectious disease diagnostics during the forecast period. The broad-scale population-based testing is required to improve prevention and control efforts for COVID-19. These tests are performed by infectious disease diagnostics; hence, it had a positive impact on this market.

Opportunity: Growing opportunities in growing economies

Developing economies such as India, South Korea, Brazil, and Mexico are expected to offer potential growth opportunities for major players operating in the infectious disease diagnostics market. This can be attributed to the high disease prevalence, large patient population, improving healthcare infrastructure, increasing disposable income, and growing medical tourism in these countries. In addition to the factors mentioned above, the Asia Pacific has emerged as an adaptive and business-friendly hub due to relatively less stringent regulations and data requirements.

Restraint: Unfavourable reimbursement scenario

Inadequate reimbursement is a major factor restraining the growth of the infectious disease diagnostics market. A major challenge that most diagnostic companies face in commercializing their tests is getting health insurers to pay for them.

Some of the prominent players in the Infectious Disease Diagnostics Market include:

• Abbott Laboratories (US)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Thermo Fisher Scientific Inc. (US)
• Siemens Healthineers AG (Germany)
• bioMérieux SA (France)

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Infectious Disease Diagnostics market.

By Product

• Reagents, Kits, and Consumables
• Instruments
• Software & Services
• By Type of Testing
• Laboratory Testing
• POC Testing

By Technology

• Immunodiagnostics
• Clinical Microbiology
• PCR
• INAAT
• DNA Sequencing & NGS
• DNA Microarray
• Other technologies

By Disease Type

• COVID-19
• HIV
• Hospital-acquired Infections
• Hepatitis
• Chlamydia Trachomatis
• Neisseria Gonorrhea
• HPV
• Tuberculosis
• Influenza
• Syphilis
• Mosquito-borne Diseases
• Other Infectious Diseases

By End User

• Diagnostic Laboratories
• Hospitals & Clinics
• Academic Research Institutes
• Other End Users

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)